BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30128025)

  • 1. Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.
    Li Z; Jiang X; Chen P; Wu X; Duan A; Qin Y
    Oncol Lett; 2018 Sep; 16(3):4033-4042. PubMed ID: 30128025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Ruffilli I; Elia G; Ragusa F; Fioravanti A; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2306-2314. PubMed ID: 29517106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of autophagy inhibitors combined with cisplatin against cisplatin-resistant nasopharyngeal cancer cells.
    Yin W; Xu J; Mao Y
    Biochem Cell Biol; 2021 Jun; 99(3):322-329. PubMed ID: 34038188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2.
    Carina V; Zito G; Pizzolanti G; Richiusa P; Criscimanna A; Rodolico V; Tomasello L; Pitrone M; Arancio W; Giordano C
    Thyroid; 2013 Jul; 23(7):829-37. PubMed ID: 23301671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P; Su Z; Zhang Z; Gao T
    Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation.
    Niu Q; Wang W; Li Y; Ruden DM; Wang F; Li Y; Wang F; Song J; Zheng K
    PLoS One; 2012; 7(7):e41035. PubMed ID: 22844424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line.
    Cheng Q; Zhang X; Xu X; Lu X
    Ann Endocrinol (Paris); 2014 Sep; 75(4):187-93. PubMed ID: 25145559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer.
    Banchi M; Orlandi P; Gentile D; Alì G; Fini E; Fontanini G; Francia G; Bocci G
    Am J Cancer Res; 2020; 10(7):2120-2127. PubMed ID: 32775005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
    Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of ATP-Binding Cassette Transporters in the Chemoresistance of Anaplastic Thyroid Cancer: A Systematic Review.
    Abbasifarid E; Sajjadi-Jazi SM; Beheshtian M; Samimi H; Larijani B; Haghpanah V
    Endocrinology; 2019 Aug; 160(8):2015-2023. PubMed ID: 31271419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue factor pathway inhibitor 2 suppresses the growth of thyroid cancer cells through by induction of apoptosis.
    Yang Y; Zhang C; Li S; Liu J; Qin Y; Ge A
    Asia Pac J Clin Oncol; 2021 Apr; 17(2):e48-e56. PubMed ID: 32043798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
    Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
    PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
    Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
    Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.